PSI Registration Exam Part 2: Practice of Pharmacy Examination

Correct: According to the Pharmaceutical Society of Ireland (PSI) guidance and the Health Service Executive (HSE) clinical protocols for the supply of emergency hormonal contraception (EHC), pharmacists must identify patients using liver enzyme-inducing medications, such as certain antiepileptics or St. John’s Wort, within the last four weeks. In these cases, the efficacy of oral EHC is significantly reduced. The primary recommendation is the insertion of a copper intrauterine device (IUD). However, if the patient opts for oral EHC, levonorgestrel is the appropriate choice, but the dose must be doubled to 3mg (two 1.5mg tablets) taken simultaneously as soon as possible. This optimization of the dosing regimen is necessary to compensate for the increased metabolism of the progestogen.

Incorrect: Recommending ulipristal acetate is incorrect because its efficacy is also reduced by enzyme inducers, and there is currently no clinical recommendation or licensed protocol to double the dose of ulipristal acetate, making it less suitable than a double dose of levonorgestrel. Providing the standard 1.5mg dose of levonorgestrel is an incorrect clinical process as it would likely result in sub-therapeutic plasma levels, increasing the risk of unintended pregnancy. Referring the patient to a neurologist or GP for a prescription is an unnecessary delay in care; Irish pharmacists are empowered to supply the double dose of levonorgestrel directly under the non-prescription supply framework to ensure timely access to emergency contraception.

Takeaway: When supplying EHC to a patient using enzyme-inducing medication, pharmacists should recommend a copper IUD or supply a double dose (3mg) of levonorgestrel.

Correct: Under the Pharmacy Act 2007 and the Regulation of Retail Pharmacy Businesses Regulations 2008 (S.I. No. 488 of 2008), the Supervising Pharmacist is legally responsible for the three-fold duty of supervising the pharmacy, managing it on a day-to-day basis, and ensuring that the sale and supply of medicinal products are conducted in accordance with the law. While process optimization allows for the delegation of certain technical tasks to trained staff, the Supervising Pharmacist must ensure that all activities are performed under the personal supervision of a pharmacist and that the overall management of the retail pharmacy business remains compliant with statutory requirements.

Incorrect: Delegating the clinical review of prescriptions to a pharmacy technician, even with a retrospective audit, is a breach of the Pharmacy Act 2007, as clinical assessment is a professional task reserved for pharmacists. Assigning the creation and review of Standard Operating Procedures (SOPs) exclusively to the Superintendent Pharmacist is incorrect because the Supervising Pharmacist has a statutory duty to manage the day-to-day operations of the specific premises, which includes ensuring local procedures are fit for purpose. Allowing a non-pharmacist owner to manage the procurement and storage of Schedule 2 and 3 Controlled Drugs is a violation of the Misuse of Drugs Regulations and the Pharmacy Act, which require these professional activities to be under the direct control and supervision of a pharmacist.

Takeaway: The Supervising Pharmacist is personally and statutorily responsible for the day-to-day management and legal compliance of the pharmacy, a duty that cannot be delegated to non-pharmacists or superseded by corporate policy.

Correct: Under the Misuse of Drugs Regulations 2017 in Ireland, Morphine Sulfate is classified as a Schedule 2 controlled drug, which necessitates both storage in a secure, locked receptacle (Safe Custody) and a formal entry in the Controlled Drugs Register for every receipt and supply. Midazolam is classified as a Schedule 3 controlled drug; in Ireland, Schedule 3 drugs are subject to Safe Custody requirements, meaning they must be stored in the controlled drugs safe, but they do not require entries in the Controlled Drugs Register. This protocol ensures full legal compliance with Irish pharmacy law while maintaining an efficient workflow.

Incorrect: Recording both medications in the Controlled Drugs Register is an incorrect application of the regulations because Schedule 3 drugs like Midazolam do not legally require register entries, and doing so can lead to administrative confusion. Storing Midazolam on general pharmacy shelves is a regulatory failure, as Schedule 3 substances are subject to Safe Custody requirements in Ireland. Storing Schedule 2 medications like Morphine Sulfate outside of a designated safe or cabinet, even in a locked room, violates the specific Safe Custody Regulations which mandate a cabinet or safe that complies with specific construction standards.

Takeaway: In Ireland, both Schedule 2 and most Schedule 3 controlled drugs require Safe Custody, but only Schedule 2 drugs require mandatory recording in the Controlled Drugs Register.

Correct: Under the PSI Code of Conduct and the Pharmacy Act 2007, the pharmacist is ultimately responsible for the professional services provided in the pharmacy. Process optimization through delegation must be supported by robust Standard Operating Procedures (SOPs) that clearly define roles. While technical aspects of dispensing can be delegated to trained pharmacy technicians, the pharmacist must personally perform the clinical assessment of the prescription and the final check of the dispensed medicine to ensure patient safety and regulatory compliance.

Incorrect: Delegating the final accuracy check to a pharmacy technician, even one with advanced training, does not align with current PSI expectations where the pharmacist must remain the final point of clinical and accuracy verification. Allowing medicines counter assistants to provide advice on Pharmacy-only medicines independently, even with an algorithm, breaches the requirement for the pharmacist to supervise all sales of medicinal products. Reassigning clinical validation to a technician is inappropriate because clinical judgment is a core professional competency that cannot be delegated to non-pharmacist staff under Irish regulatory frameworks.

Takeaway: Delegation in an Irish pharmacy context must be governed by SOPs that preserve the pharmacist’s role in clinical decision-making and final product verification.

Correct: Under the Pharmaceutical Society of Ireland (PSI) Code of Conduct and the principles of Open Disclosure, pharmacists have an ethical and professional obligation to be open, honest, and transparent when a medication error occurs. The correct approach involves promptly informing the patient of the error, offering a sincere apology, providing clinical guidance on what to monitor, and documenting the event in the pharmacy’s incident log. This process optimization ensures patient safety is prioritized while facilitating a root cause analysis to prevent future occurrences, aligning with the Patient Safety (Notifiable Patient Safety Incidents) Act 2023 framework.

Incorrect: Delaying the conversation until the patient returns for a refill is inappropriate because the duty of candor requires timely communication to ensure the patient can monitor for adverse effects immediately. Making disclosure contingent upon a physician’s assessment of clinical risk is incorrect because the patient has a right to be informed of errors in their care regardless of the perceived level of harm. Correcting internal records and implementing new checks without informing the patient is a breach of professional transparency and fails to meet the regulatory requirements for open disclosure in Irish pharmacy practice.

Takeaway: The duty of candor in Irish pharmacy practice requires proactive, honest communication with the patient and systematic internal reporting to improve dispensing processes and maintain public trust.

Correct: Under the Safety, Health and Welfare at Work (Chemical Agents) Regulations and PSI Professional Standards, a risk assessment must prioritize the hierarchy of controls. An impact assessment must evaluate how the physical form of the agent, such as the potential for powder aerosolization during weighing, interacts with existing engineering controls like local exhaust ventilation or containment hoods. This ensures that the impact on the health of all staff in the vicinity is mitigated through collective protection measures rather than relying on individual behavior alone.

Incorrect: Relying primarily on the provision of high-grade personal protective equipment (PPE) as the definitive measure is incorrect because Irish health and safety legislation dictates that PPE is the last resort in the hierarchy of controls and should only be used when engineering or administrative controls are insufficient. Restricting the assessment to the physical properties listed in the Safety Data Sheet (SDS) is inadequate as it fails to account for the specific operational environment and the “at work” context required by the Health and Safety Authority (HSA). Implementing health surveillance only after a confirmed accidental exposure is a reactive failure; Irish regulations require proactive risk identification and, where necessary, preventative health surveillance to monitor the effectiveness of control measures before an incident occurs.

Takeaway: A robust impact assessment for hazardous compounding must evaluate the interaction between the substance’s properties and the pharmacy’s engineering controls to ensure collective protection according to the hierarchy of controls.

Correct: Under the Regulation of Retail Pharmacy Businesses Regulations 2008 (S.I. No. 488 of 2008) in Ireland, a retail pharmacy must be constructed and laid out to ensure the safe and proper storage, preparation, and sale of medicinal products. This includes a mandatory requirement for a dedicated area for private consultations where conversations between the pharmacist and a patient cannot be overheard by others. Additionally, the dispensary must be a clearly defined area where public access is strictly prohibited to allow the pharmacist to maintain effective supervision and control over the medicinal products.

Incorrect: One approach suggests that a designated seating area within the pharmacist’s line of sight is sufficient for patient counseling, but this fails to meet the legal requirement for a private area that ensures confidentiality and prevents conversations from being overheard. Another approach proposes that the dispensary must be enclosed by a floor-to-ceiling physical barrier; while security is required, Irish regulations do not specifically mandate a floor-to-ceiling barrier as the only means of restricting access, provided the area is clearly demarcated and unauthorized entry is prevented. A third approach focuses on placing the consultation area at the main entrance for accessibility, which does not address the primary regulatory concern of privacy. Furthermore, prioritizing the rapid retrieval of Controlled Drugs over secure storage requirements or cluttering the dispensary with non-medicinal retail items would violate the standards for the orderly and safe management of a pharmacy premises.

Takeaway: Irish pharmacy regulations mandate a dedicated private consultation area to ensure patient confidentiality and a restricted-access dispensary to maintain the safe supervision of medicines.

Correct: Under the PSI Guidelines on the Operation of Retail Pharmacy Businesses, Standard Operating Procedures (SOPs) must be site-specific and reflect the actual working practices of the individual pharmacy. The Superintendent Pharmacist is responsible for the systems in place, and the Supervising Pharmacist must ensure the pharmacy operates in a safe manner. This includes ensuring that SOPs are reviewed, approved by the Superintendent or Supervising Pharmacist, and that all staff members are trained on and have signed the specific versions relevant to their roles to ensure accountability and safety.

Incorrect: Adopting generic templates from a professional body or corporate office without local adaptation fails to meet the requirement that SOPs must be specific to the premises, layout, and staffing of the individual retail pharmacy business. Delegating the final approval of SOPs entirely to a pharmacy technician is inconsistent with the statutory responsibilities of the Superintendent and Supervising Pharmacists under the Pharmacy Act 2007. Updating SOPs only in response to dispensing errors is insufficient, as Irish regulatory standards require proactive, periodic reviews (at least every two years) to ensure the procedures remain fit for purpose regardless of whether an incident has occurred.

Takeaway: SOPs must be site-specific, approved by the Superintendent or Supervising Pharmacist, and supported by documented staff training and periodic reviews to comply with PSI standards.

Correct: Under the Health (Pricing and Supply of Medical Goods) Act 2013, when a pharmacist receives a prescription for a branded product that is on the Health Products Regulatory Authority (HPRA) list of interchangeable medicines, and the prescriber has not written Do Not Substitute for clinical reasons, the pharmacist must offer the patient the option of a less expensive interchangeable product. The pharmacist is required to explain the substitution to the patient, ensuring they understand that the active ingredient and strength remain the same despite differences in brand name or packaging. If the patient agrees, the pharmacist dispenses the interchangeable product and maintains appropriate records of the substitution.

Incorrect: One approach suggests that the pharmacist has the authority to substitute a medicine even if the prescriber has explicitly written Do Not Substitute on the prescription, provided the pharmacist believes the generic version is equally effective. This is incorrect because the Act specifies that a prescriber’s clinical decision to prohibit substitution must be respected. Another approach involves the pharmacist substituting the medicine automatically without informing the patient or offering a choice, which fails to meet the legal requirement to inform the patient of the substitution and the availability of a less expensive option. A third approach suggests that the pharmacist must contact the prescriber to obtain a new prescription or verbal authorization before every substitution of an interchangeable medicine. This is incorrect as the Act was specifically designed to allow pharmacists to substitute items on the HPRA list without seeking further authorization from the prescriber, provided the statutory conditions are met.

Takeaway: Under Irish law, pharmacists may substitute medicines on the HPRA interchangeable list provided no clinical Do Not Substitute instruction exists and the patient is informed of the choice.

Correct: Under the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 2) Regulations 2015 (S.I. No. 449 of 2015) in Ireland, pharmacists are permitted to supply specific prescription-only medicines (POMs) to schools for emergency use. This includes salbutamol inhalers and adrenaline auto-injectors. The supply must be supported by a signed order from the school principal, who is the person in charge of the organization. The pharmacist must verify that the school is a recognized educational institution, ensure the medicines are labeled for emergency use, and retain the signed order for a period of two years.

Incorrect: Requiring a named-patient prescription for a specific student is an incorrect approach because the 2015 regulations were specifically introduced to allow schools to hold stock for any student or person on the premises experiencing an emergency, rather than relying on individual prescriptions. Treating the supply as a standard over-the-counter transaction or recording it in the Poisons Book is legally insufficient because these medicines are POMs and the emergency supply framework has its own specific documentation and labeling requirements that must be followed. Suggesting that the pharmacist must be present to administer the first dose or that a general request from a board of management is sufficient fails to recognize the specific legal requirement for a signed order from the principal and the provision that allows trained non-medical staff to administer these medicines in life-threatening situations.

Takeaway: Pharmacists in Ireland can supply specific emergency medicines to schools using a signed order from the principal, provided they adhere to the specific record-keeping and labeling requirements set out in S.I. No. 449/2015.

Correct: Under the Pharmacy Act 2007, the Superintendent Pharmacist is legally responsible for the management and control of the sale and supply of medicinal products for the entire retail pharmacy business, including corporate oversight. In contrast, the Supervising Pharmacist must have at least three years of post-registration experience and is specifically responsible for the day-to-day management and control of a single, specific registered premises.

Incorrect: One approach incorrectly suggests that the Superintendent Pharmacist must be physically present for a minimum of 30 hours per week at every individual premises within a group, which is not a statutory requirement and confuses personal supervision with management roles. Another approach misplaces the burden of clinical governance for a whole group onto the Supervising Pharmacist, when this responsibility actually rests with the Superintendent. A third approach suggests that a single pharmacist may act as the Supervising Pharmacist for multiple locations within a specific region, which is prohibited as the Act requires a dedicated Supervising Pharmacist for each individual pharmacy to ensure proper professional standards.

Takeaway: The Pharmacy Act 2007 requires a Superintendent Pharmacist to oversee the entire retail pharmacy business while a Supervising Pharmacist manages the daily operations of one specific premises.

Correct: The pharmacist administers the vaccine following a clinical consultation and risk assessment, ensuring they possess valid PSI-approved training and CPR certification, and records the administration in the national immunization system. Under the Medicinal Products (Prescription and Control of Supply) Regulations in Ireland, pharmacists are legally empowered to supply and administer specific vaccines, such as the influenza vaccine, without a traditional individual prescription, provided they adhere to the statutory requirements regarding training, protocols, and documentation.

Incorrect: Requiring a physical prescription from a General Practitioner for every patient is an incorrect interpretation of the law, as the regulations provide a specific framework for pharmacists to supply and administer these medicines independently under protocol. Administering the vaccine based on verbal consent while omitting the provision of the National Immunisation Advisory Committee (NIAC) information materials fails to meet the legal and professional standards for informed consent. Delegating the administration to a pharmacy student who has not yet completed the specific PSI-approved practical training and CPR certification is prohibited, as the legal authority to administer is strictly limited to practitioners who have fulfilled all regulatory training mandates.

Takeaway: Legal administration of vaccines by pharmacists in Ireland requires adherence to specific training standards, clinical protocols, and mandatory record-keeping as defined by the Medicinal Products Regulations.

Correct: The Superintendent Pharmacist must exercise overall management and control of the retail pharmacy business, ensuring that the business is conducted in accordance with the law and that a Supervising Pharmacist is in place for each specific premises. This is a statutory requirement under the Pharmacy Act 2007 in Ireland, which establishes that while a Supervising Pharmacist manages the day-to-day operations of a specific site, the Superintendent Pharmacist carries the ultimate legal responsibility for the governance, management, and control of the entire retail pharmacy business.

Incorrect: Requiring a constant physical presence at a single premises during all opening hours describes the duty of the pharmacist in charge or the Supervising Pharmacist at a specific location, rather than the Superintendent’s broader management role across the business. Delegating all statutory responsibility to a Supervising Pharmacist is legally impossible under Irish regulations, as the Pharmacy Act 2007 mandates that the Superintendent retains the ultimate responsibility for the management and control of the business regardless of local supervision. Prioritizing financial auditing and commercial procurement over legislative compliance misinterprets the role, as the Superintendent’s primary statutory function is to ensure the professional and legal integrity of the pharmacy services and compliance with PSI (Pharmaceutical Society of Ireland) standards.

Takeaway: Under the Pharmacy Act 2007, the Superintendent Pharmacist is the individual legally responsible for the overarching management and control of the retail pharmacy business and its compliance with all relevant pharmacy legislation.

Correct: Under the Health Service Executive (HSE) guidelines for the Drugs Payment Scheme in Ireland, the monthly threshold applies to a family unit rather than individuals. A family is defined as an adult, their spouse or partner, and children under 18 years of age, or under 23 years of age if in full-time education. By ensuring all eligible members are correctly linked to a single DPS registration, the pharmacist ensures the family does not pay more than the statutory monthly limit for approved items dispensed within a calendar month.

Incorrect: Treating family members as separate individual accounts for the purpose of the threshold would lead to a breach of the scheme’s intent, as the family might pay the maximum amount multiple times. Including all adult children based solely on residency or lack of income is incorrect because the specific regulatory requirement for dependents aged 18 to 23 is enrollment in full-time education; those over 23 or not in education must have their own registration. Suggesting that overpayments can be carried forward as a credit to the following month is inconsistent with the PCRS reimbursement structure, which is strictly based on a monthly cap; any overpayment must be reclaimed by the patient from the HSE directly if they used multiple pharmacies or were overcharged.

Takeaway: The Drugs Payment Scheme provides a monthly financial cap on approved medication costs for a defined family unit, necessitating the inclusion of all eligible dependents under a single registration to ensure regulatory compliance.

Correct: The pharmacist should proactively communicate with the prescriber to discuss the clinical risk, suggest a temporary suspension of the statin or an alternative antibiotic, and ensure the intervention is recorded in the pharmacy patient medication record. This aligns with Principle 5 of the PSI Code of Conduct, which emphasizes working with other healthcare professionals to enhance patient safety and ensure the best possible health outcomes through effective communication and professional cooperation.

Incorrect: Suggesting the patient decide between treatments is inappropriate as it shifts the clinical responsibility to the patient and fails to fulfill the pharmacist duty of care. Dispensing the medication first and notifying the prescriber later is unsafe if a significant interaction is identified, as the pharmacist has a professional obligation to prevent harm before it occurs. Unilaterally adjusting the dose or regimen without prior authorization from the prescriber exceeds the current legal scope of practice for pharmacists in Ireland under the Pharmacy Act 2007, unless a specific collaborative practice agreement or protocol is in place.

Takeaway: Effective collaboration requires timely, evidence-based communication with prescribers and meticulous documentation to ensure patient safety and regulatory compliance under the PSI Code of Conduct.

Correct: To comply with the Animal Remedies Regulations in Ireland, a pharmacist must ensure that a veterinary prescription includes the registration number of the veterinary practitioner and specifies the withdrawal period for the animal remedy, particularly when the treatment involves food-producing species. This ensures both the legitimacy of the prescriber and the safety of the food chain.

Incorrect: Suggesting that a veterinary prescription is valid for twelve months is incorrect because, under Irish law, the standard validity period for a veterinary prescription is six months from the date of issue. Requiring the PPS number of the animal owner is not a legal requirement for the validity of a veterinary prescription in Ireland. Accepting a verbal instruction for a prescription-only animal remedy with a 72-hour follow-up is not a standard provision for veterinary medicines in the same way it is applied to certain human emergency supplies; a valid written prescription must generally be present at the time of supply for controlled or prescription-only animal remedies.

Takeaway: A valid veterinary prescription in Ireland must contain specific statutory information, including the prescriber’s registration number and the relevant withdrawal period, and remains valid for a maximum of six months.

Correct: A clinical audit in an Irish pharmacy context must follow a systematic cycle that involves identifying evidence-based standards or PSI guidelines, measuring current practice against these criteria, and implementing an action plan to address any identified gaps. This approach aligns with the PSI Core Competency Framework and clinical governance principles, ensuring that clinical services are safe, effective, and subject to continuous quality improvement.

Incorrect: Focusing primarily on patient satisfaction scores and the total number of consultations provides a measure of service utilization and perceived quality but fails to evaluate clinical outcomes or adherence to professional standards. Prioritizing a review of the financial sustainability and reimbursement claims under the Primary Care Reimbursement Service (PCRS) constitutes a business or administrative audit rather than a clinical audit of patient outcomes. Relying on informal peer observation and verbal feedback lacks the objective data collection and structured comparison against pre-defined benchmarks necessary for a robust clinical audit process.

Takeaway: A clinical audit must be a structured, criteria-based process aimed at improving patient care through systematic review and objective change.

Correct: Refraining from sharing specific clinical details that could lead to patient re-identification, even within private forums, as the PSI Code of Conduct applies to all digital communications regardless of privacy settings. This aligns with the PSI Guidance on Professionalism in Social Media, which emphasizes that pharmacists must maintain patient confidentiality and professional standards in all online interactions. The risk of jigsaw identification means that even without a name, a patient could be identified by the context provided, such as the date, location, or specific medical condition.

Incorrect: Relying on high privacy settings or pseudonyms is insufficient because the PSI Code of Conduct applies to the individual’s conduct regardless of the platform’s perceived privacy or the use of an alias; the pharmacist remains accountable for their actions. Assuming that closed professional groups provide the same legal protections as formal clinical handovers is incorrect, as unauthorized disclosure of patient information to a broad group of peers still constitutes a breach of confidentiality and data protection laws. Focusing solely on the removal of posts after negative feedback fails to address the initial professional lapse and does not fulfill the proactive duty to maintain professional boundaries and public trust from the outset.

Takeaway: Pharmacists must uphold the PSI Code of Conduct in all digital spaces, ensuring that patient confidentiality is maintained and professional boundaries are respected, irrespective of privacy settings or group membership.

Correct: Under the Medicinal Products (Prescription and Control of Supply) Regulations in Ireland, specifically amendments introduced to curb the illicit manufacture of methamphetamine, a pharmacist is legally prohibited from supplying more than 720mg of pseudoephedrine in a single transaction. Even when a patient presents a plausible clinical need or a request based on convenience for travel, the pharmacist must adhere to this statutory limit. The correct professional action is to supply the maximum legal amount (or less, based on clinical judgment) and provide counseling on alternative therapies or the necessity of seeking local medical assistance abroad, ensuring both legal compliance and patient safety.

Incorrect: Recording a patient’s passport details or destination of travel does not provide a legal exemption to exceed the 720mg pseudoephedrine limit; the restriction is absolute per transaction regardless of documentation. While professional discretion is a cornerstone of practice, it cannot be used to override specific quantitative statutory restrictions designed for precursor control. Emergency supply regulations under Irish law pertain to the supply of Prescription Only Medicines (POM) in specific circumstances and do not offer a mechanism to bypass the maximum transaction limits for non-prescription pseudoephedrine or ephedrine products.

Takeaway: Pharmacists in Ireland must strictly observe the 720mg pseudoephedrine and 180mg ephedrine transaction limits as these are statutory requirements that cannot be exceeded through professional discretion or patient documentation.

Correct: Under the Medicinal Products (Prescription and Control of Supply) Regulations in Ireland, a prescription issued in another EU or EEA member state must contain specific mandatory data elements to be valid for dispensing. These include the prescriber details such as their professional qualification and direct contact information like an email address or telephone number with the international prefix. If these details are missing, the pharmacist must exercise professional clinical judgment and take proactive steps to verify the prescriber’s identity and registration status via the relevant national competent authority or registry in the country of origin. Once the missing information is confirmed and the prescription is deemed authentic, the pharmacist may proceed with dispensing, provided the medication is not a Schedule 2 or 3 controlled substance, which are prohibited from being dispensed on cross-border prescriptions in Ireland.

Incorrect: One approach involves providing an emergency supply while ignoring the technical deficiencies of the cross-border prescription. This is incorrect because the regulations for emergency supply at the request of a patient have specific criteria that must be met, and using an invalid cross-border script as the sole basis without verification fails to meet the legal requirements for recognizing foreign prescriptions. Another approach suggests that all non-English prescriptions must be translated by an official body. This is a misconception; while the pharmacist must be able to clearly understand the prescription to ensure safety, there is no statutory requirement for a formal third-party translation service if the pharmacist can accurately interpret the details. A final approach suggests performing a generic substitution immediately. While generic substitution is part of Irish practice, the primary issue is the legal validity of the prescription itself; a pharmacist cannot legally dispense or substitute against a prescription that fails to meet the mandatory cross-border data requirements until those requirements are satisfied through verification.

Takeaway: For a cross-border EU/EEA prescription to be legally valid in Ireland, it must contain all regulatory data elements, and pharmacists must verify any missing mandatory prescriber information before dispensing.

Correct: Sourcing medicinal products in Ireland must strictly adhere to the Pharmacy Act 2007 and the Regulation of Retail Pharmacy Businesses Regulations 2008. A pharmacist must ensure that all medicines are obtained from a supplier who holds a Wholesaler Authorisation granted by the Health Products Regulatory Authority (HPRA) or an equivalent competent authority in another EEA member state. Furthermore, under the Falsified Medicines Directive (FMD), the pharmacist is responsible for ensuring the integrity of the supply chain by verifying the safety features (the unique identifier and anti-tampering device) via the National Medicines Verification System (NMVS) to prevent falsified medicines from entering the legal supply chain.

Incorrect: Procuring stock from another retail pharmacy as a standard sourcing strategy is inappropriate because retail pharmacies are not authorized wholesalers; while small-scale emergency supply between pharmacies is permitted, it cannot be used to circumvent the authorized supply chain. Sourcing from a hospital surplus is incorrect because hospitals typically do not hold the necessary wholesale distribution authorizations to supply retail pharmacies. Obtaining products from non-EEA jurisdictions without the specific import licenses and marketing authorizations required by the HPRA violates Irish and EU law, regardless of the product’s status in its country of origin.

Takeaway: To maintain supply chain integrity and patient safety, pharmacists must source medicines exclusively from HPRA-authorized wholesalers and comply with all FMD verification requirements.

Correct: Conduct a thorough internal investigation including a review of all recent prescriptions and invoices, and if the discrepancy remains unresolved and is deemed significant or suspicious, report the matter to the Pharmaceutical Society of Ireland (PSI) and the Garda Siochana. Under the Misuse of Drugs Regulations 2017 and PSI professional standards, the Supervising Pharmacist is responsible for the safe management of controlled drugs. An unresolved discrepancy in Schedule 2 medications requires immediate action to identify the cause, and if it cannot be accounted for by a clerical error, it must be reported to the regulator and law enforcement to prevent potential diversion and ensure public safety.

Incorrect: Adjusting the register balance to match physical stock without identifying the source of the error is a breach of the Misuse of Drugs Regulations, as the register must be a true reflection of all legally received and supplied controlled drugs. Delaying the reconciliation process for 48 hours to wait for specific staff members is inappropriate because it hinders a timely investigation and may allow further discrepancies to occur. Documenting the issue only for internal monitoring fails to meet the professional duty to escalate significant concerns regarding high-risk medications to the appropriate authorities.

Takeaway: All unresolved significant discrepancies in Schedule 2 controlled drug stocks must be investigated immediately and reported to the PSI and Garda Siochana to maintain the integrity of the controlled drug governance framework.

Correct: Under the EU Guidelines on Good Distribution Practice (GDP) and the Medicinal Products (Control of Wholesale Distribution) Regulations in Ireland, the Responsible Person must ensure that all suppliers of medicinal products hold a valid wholesale distribution authorisation or a manufacturing authorisation. Verification must be performed prior to any procurement of medicinal products. This verification must be conducted by checking the EudraGMDP database or obtaining a copy of the authorisation from the relevant national competent authority, such as the Health Products Regulatory Authority (HPRA). Relying on supplier claims or clinical urgency does not exempt the wholesaler from this mandatory safety requirement designed to prevent falsified medicines from entering the legal supply chain.

Incorrect: Conducting an internal quality audit and physical inspection of the stock while keeping it in quarantine is insufficient because GDP requires the legal status of the supplier to be confirmed before the transaction occurs. Physical inspection cannot reliably detect sophisticated falsified medicines. Accepting a signed affidavit from a supplier’s Responsible Person is not a recognized method of regulatory verification; the wholesaler has an independent duty to verify the supplier’s status through official regulatory channels. Reclassifying the transaction as a brokering arrangement is inappropriate as brokers are also subject to registration and GDP requirements, and such a reclassification would be seen as an attempt to circumvent the strict procurement controls mandated for wholesale distribution authorisation holders.

Takeaway: A wholesale distribution authorisation holder must independently verify the regulatory status of every supplier through official databases before procuring any medicinal products to ensure the integrity of the supply chain.

Correct: Under the Regulation of Retail Pharmacy Businesses Regulations 2008 (S.I. No. 488 of 2008), a record of every prescription dispensed, excluding those under specific state schemes where a duplicate is retained, must be entered into the Prescription Book. When an omission is identified, the pharmacist is professionally and legally obligated to rectify the record retrospectively. This ensures the traceability of all medicinal products supplied from the pharmacy and maintains the integrity of the legal register required by the PSI. The entry must accurately reflect the date the medicine was actually supplied to the patient.

Incorrect: Suggesting that physical filing of the original prescription serves as a legal substitute for a Prescription Book entry is incorrect, as Irish law specifically requires the entry in the register regardless of how the paper is filed. Limiting retrospective entries only to Controlled Drugs is a common misconception; while CD registers are vital, the Prescription Book must contain all non-state scheme prescriptions. Simply documenting the error in the Quality Management System (QMS) without correcting the missing entries fails to address the ongoing breach of statutory record-keeping requirements.

Takeaway: All private prescriptions must be recorded in the Prescription Book to comply with the Regulation of Retail Pharmacy Businesses Regulations, and any identified omissions must be corrected immediately to ensure a complete legal audit trail.

Correct: Under the Children First Act 2015 and the PSI Code of Conduct, pharmacists in Ireland are designated as mandated persons. When a pharmacist has a reasonable concern that a child may have been, is being, or is at risk of being abused or neglected, they have a statutory obligation to report this concern to Tusla, the Child and Family Agency. This legal duty to protect the child takes precedence over the duty of confidentiality to the parent or guardian. Documentation of the observations and the rationale for the report is essential for professional accountability.

Incorrect: Delaying a report to gather more definitive evidence or to monitor the situation over subsequent visits fails to meet the statutory requirement of reporting as soon as reasonable grounds for concern are established. Relying solely on another healthcare professional, such as a General Practitioner, to initiate the report does not discharge the pharmacist’s individual legal responsibility as a mandated person under Irish law. While consulting with a Supervising Pharmacist is good practice for support, the decision to report should be based on the mandated person’s own assessment of the risk, and the report must be directed to Tusla rather than the Health Service Executive for child-related safeguarding concerns.

Takeaway: Pharmacists in Ireland must fulfill their statutory duty as mandated persons by reporting reasonable safeguarding concerns regarding children directly to Tusla, prioritizing the safety of the child over the duty of confidentiality.

Correct: Quarantining the stock and obtaining stability data from the manufacturer ensures that decisions are based on evidence-backed safety profiles. This aligns with PSI Guidelines on the Sourcing, Storage and Disposal of Medicinal Products, which require that any medicinal products that have been exposed to temperatures outside of their storage instructions must be quarantined and their quality assessed before any further use or disposal.

Incorrect: Prioritizing the dispensing of potentially compromised stock without stability data risks patient safety and violates Good Distribution Practice principles. Relying on a quick return to the correct temperature range without investigating the duration of the excursion fails to account for cumulative heat exposure and the specific sensitivity of the medicinal products. Using visual inspection as the sole criterion for product integrity is insufficient, as chemical degradation or loss of potency in thermolabile products often occurs without observable physical changes.

Takeaway: Any deviation from the required 2 to 8 degrees Celsius storage range must be managed by quarantining the stock and conducting a formal impact assessment supported by manufacturer stability data.

Correct: Under the Misuse of Drugs Regulations in Ireland, a pharmacist may supply Schedule 2 or 3 controlled drugs to a practitioner provided a valid requisition is received. The legal requirements for this requisition are that it must be in writing, signed by the recipient, state the recipient’s name, address, and profession or occupation, and specify the total quantity of the drug and the purpose for which it is required. The pharmacist must also be reasonably satisfied that the signature is that of the person purporting to sign it and that the person is a practitioner.

Incorrect: Requiring the total quantity to be stated in both words and figures is a specific legal requirement for prescriptions for Schedule 2 and 3 controlled drugs under Irish law, but this specific formatting rule does not extend to requisitions. Including a specific patient name on a requisition is incorrect because a requisition is intended for obtaining professional stock for practice use rather than for a specific individual. While the use of standardized forms is encouraged for consistency, the Misuse of Drugs Regulations do not mandate a specific Health Service Executive (HSE) standardized form as the only legal means of requisitioning, provided all statutory information is present. Notification to the Pharmaceutical Society of Ireland (PSI) for every individual supply made via requisition is not a regulatory requirement, though the transaction must be recorded in the Controlled Drugs Register.

Takeaway: A valid requisition for controlled drugs in Ireland must be in writing, signed by the practitioner, and specify their professional details, the quantity of the drug, and the intended professional purpose.

Correct: Under the Pharmacy Act 2007 and the PSI (Supervising Pharmacist) Rules, the Supervising Pharmacist is required to be in whole-time charge of the pharmacy. If a Supervising Pharmacist is to be absent for a continuous period exceeding four weeks, the Pharmaceutical Society of Ireland (PSI) must be formally notified of the change, and a new Supervising Pharmacist must be appointed to take over the statutory duties of management and control. This ensures that a designated individual is always legally responsible for the professional and clinical management of the retail pharmacy business.

Incorrect: Delegating statutory responsibilities to a senior staff pharmacist through an internal arrangement without notifying the regulator is incorrect because the role of Supervising Pharmacist is a registered position with specific legal accountability to the PSI. Operating the pharmacy with a locum while the Superintendent Pharmacist provides remote oversight is insufficient, as the law requires a specific Supervising Pharmacist to be in whole-time charge of the premises to ensure day-to-day compliance. Suggesting that a Supervising Pharmacist can maintain legal responsibility during a long-term absence by performing a retrospective review of records is a failure to meet the requirement for active, ongoing management and control of the pharmacy’s operations.

Takeaway: A formal notification to the PSI and the appointment of a new Supervising Pharmacist are mandatory requirements when the current Supervising Pharmacist is absent for more than four weeks.

Correct: Under the terms of the HSE Pharmacy Contract and the Health Act 1970, pharmacists are required to maintain a robust internal audit trail for all claims submitted to the Primary Care Reimbursement Service. This includes the retention of the original prescription, clear evidence of the dispensing event, and where required by specific scheme guidelines, documentation of patient receipt. This physical and digital evidence is essential to substantiate that the professional service was actually rendered and that the claim is valid during a PCRS inspection or audit.

Incorrect: Relying solely on electronic claim submission records is insufficient because the PCRS requires the underlying source documentation, such as the original prescription, to verify the legality and accuracy of the claim. While digital scans are useful for internal management, they do not replace the legal requirement to retain original paper prescriptions for the duration specified in the Pharmacy Act and Misuse of Drugs Regulations. Submitting claims based on the date the prescription was written, rather than the date the medication was actually dispensed to the patient, is a procedural error that can lead to claim rejection or recovery of funds during an audit, as reimbursement is predicated on the supply of the medicine.

Takeaway: Successful PCRS audit compliance relies on maintaining original documentation and verifiable evidence of dispensing for every claim submitted under the state schemes.